Received July 10, 2003; revisions received Feb. 20, April 14, and Aug. 5, 2004; accepted Sept. 9, 2004. From the Department of Psychiatry, University of California, San Diego; the Department of Psychiatry, San Diego VA Healthcare System, La Jolla, Calif.; the Department of Molecular Medicine, Karolinska Institutet and Karolinska Sjukhuset, Stockholm; and the Department of Nephrology, St. Luke’s Hospital, Kansas City, Mo. Address correspondence and reprint requests to Dr. Kelsoe, Department of Psychiatry, 0603, University of California, San Diego, La Jolla, CA 92093-0603; email@example.com (e-mail). Supported by Novartis Pharma AG; by the VA Mental Illness Research, Education and Clinical Center of Veterans Integrated Service Network 22 (VISN22); by grants to Dr. Kelsoe from the VA, from NIMH (MH-47612, MH-59567), from the University of California, San Diego, Mental Health Clinical Research Center (MH-30914), and from the University of California, San Diego, General Clinical Research Center (M01 RR-00827); and by grants to Dr. Schalling from the Swedish Research Council, from the Karolinska Hospital and Institutet, from the Söderström Königska Foundation, and from the Söderberg Foundation. Dr. Kelsoe is a founder of and holds equity in Psynomics, Inc. The authors thank the family members who participated for making the study possible.